https://www.selleckchem.com/products/Perifosine.html Rhamnolipid is the main group of biosurfactants predominantly produced by Pseudomonas aeruginosa, a ubiquitous and opportunistic pathogen, which limits its large-scale exploitation. Thus, cost-effective rhamnolipid production from a newly isolated nonpathogenic Enterobacter sp. UJS-RC was investigated. The highest rhamnolipid production (4.4 ± 0.2 g/L) was achieved in a medium constituting agroindustrial wastes (sugarcane molasses and corn steep liquor) as substrates. Rhamnolipid exhibited reduced surface tension to 72-28 mN/m with an emulsification index of 75%. The structural analyses demonstrated the presence of methoxyl, carboxyl, and hydroxyl groups in rhamnolipid. Mass spectra indicated eight rhamnolipid congeners, where dirhamnolipid (m/z 650.01) was the dominant congener. Rhamnolipid inhibited biofilm formation of Staphylococcus aureus in a dose-dependent manner, supported by scanning electron microscopy disclosing the disruption of the microcolony/exopolysaccharide matrix. Rhamnolipid's ability to generate reactive oxygen species has thrown light on the mechanism through which the killing of test bacteria may occur.Immunoassays have been used for decades in clinical laboratories to quantify proteins in serum and plasma samples. However, their limitations make them inappropriate in some cases. Recently, mass spectrometry (MS) based proteomics analysis has emerged as a promising alternative method when seeking to assess panels of protein biomarkers with a view to providing protein profiles to monitor health status. Up to now, however, translation of MS-based proteomics to the clinic has been hampered by its complexity and the substantial time and human resources necessary for sample preparation. Plasma matrix is particularly tricky to process as it contains more than 3000 proteins with concentrations spanning an extreme dynamic range (1010). To address this preanalytical challenge, we designed a microfluidi